Common marmosets (Callithrix jacchus) are attracting attention as animal models in preclinical studies for drug development. However, cytochrome P450s (P450s), major drug-metabolizing enzymes, have not been fully identified and characterized in marmosets. In this study, based on the four novel P450 4F genes found on the marmoset genome, we successfully isolated P450 4F2, 4F3B, 4F11, and 4F12 cDNAs in marmoset livers. Deduced amino acid sequences of the four marmoset P450 4F forms exhibited high sequence identities (87%-93%) to the human and cynomolgus monkey P450 4F homologs. Marmoset P450 4F3B and 4F11 mRNAs were predominantly expressed in livers, whereas marmoset P450 4F2 and 4F12 mRNAs were highly expressed in small intestines and livers. Four marmoset P450 4F proteins heterologously expressed in Escherichia coli catalyzed the v-hydroxylation of leukotriene B 4 . In addition, marmoset P450 4F12 effectively catalyzed the hydroxylation of antiallergy drug ebastine, a human P450 2J/4F probe substrate. Ebastine hydroxylation activities by small intestine and liver microsomes from marmosets and cynomolgus monkeys showed greatly higher values than those of humans. Ebastine hydroxylation activities by marmoset and cynomolgus monkey small intestine microsomes were inhibited (approximately 60%) by anti-P450 4F antibodies, unlike human small intestine microsomes, suggesting that contribution of P450 4F enzymes for ebastine hydroxylation in the small intestine might be different between marmosets/ cynomolgus monkeys and humans. These results indicated that marmoset P450 4F2, 4F3B, 4F11, and 4F12 were expressed in livers and/or small intestines and were functional in the metabolism of endogenous and exogenous compounds, similar to those of cynomolgus monkeys and humans.
Introduction
Common marmosets (Callithrix jacchus), New World primates, have attracted much attention as the nonhuman primate model in various biomedical fields, including drug development, neuroscience, and regenerative medicine, due to their genetic closeness to humans, small body size, high reproductive efficiency, and applicability of transgenic technologies (Kishi et al., 2014) . Cynomolgus monkeys (Macaca fascicularis) and rhesus monkeys (Macaca mulatta), Old World primates, have been extensively used for evaluating drug candidate compounds and are important species in preclinical drug development studies.
Cytochrome P450s (P450s), the major drug-metabolizing enzymes consisting of multiple subfamilies, play an important role in the metabolism of endogenous and exogenous compounds. In humans, the P450 4F subfamily consists of seven members: P450 4F2, 4F3A, 4F3B, 4F8, 4F11, 4F12, and 4F22 forms expressed in various tissues, including livers and kidneys (P450 4F2, 4F3B, 4F11, and 4F12), intestines (P450 4F2 and 4F12), myeloid cells (P450 4F3A), seminal vesicles (P450 4F8), and the epidermis (P450 4F8 and 4F22) (Cui et al., 2000; Bylund et al., 2001; Christmas et al., 2001; Stark et al., 2003; Kelly et al., 2011) . Most of these forms catalyze v-hydroxylation of eicosanoids, including arachidonic acid, leukotrienes, and prostaglandin (Hsu et al., 2007) . These metabolites play essential roles in many biologic processes such as inflammatory response, tumor progression, angiogenesis, and blood pressure regulation (Johnson et al., 2015) . In addition, P450 4F12 reportedly metabolizes a number of antiallergy drugs, including ebastine, astemizole, and terfenadine (Hashizume et al., 2002; Eksterowicz et al., 2014) . P450 4F2 and/or 4F3B also are responsible for the O-demethylation of the antiparasitic prodrug pafuramidine and the v-hydroxylation of fingolimod, an oral drug for relapsing multiple sclerosis (Wang et al., 2007; Jin et al., 2011) . These findings suggest that P450 4F enzymes are responsible for endogenous and xenobiotic biotransformations. P450 4F forms have been identified in various species, including mice (P450 4F13, 4F14, 4F15, 4F16, 4F17, 4F18, 4F37, 4F39, and 4F40), rats (P450 4F1, 4F4, 4F5, 4F6, 4F17, 4F18, 4F37, and 4F40), pigs (P450 4F55), cynomolgus monkeys (P450 4F2, 4F3B, 4F11, and 4F12), rhesus monkeys (P450 4F8, 4F12, and 4F22), and orangutans (P450 4F11 and 4F12). In cynomolgus monkeys, P450 4F2, 4F3B, 4F11, and 4F12 mRNAs were expressed in livers, kidneys, and/or jejuna (Uno et al., 2007) . Cynomolgus monkey P450 4F2, 4F3B, and 4F11 proteins heterologously expressed in Escherichia coli metabolized arachidonic acids . Cynomolgus monkey P450 4F-like enzymes are major catalysts of ebastine hydroxylation in the small intestines (Hashizume et al., 2001 ).
However, despite their potential importance as a primate model in drug development, marmoset P450 4F forms have not been identified.
More than 17 marmoset P450 forms have been identified to date belonging to the P450 1A, 1B, 2A, 2B, 2C, 2D, 2E, 2J, and 3A subfamilies (Igarashi et al., 1997; Schulz et al., 1998; Mayumi et al., 2013; Uehara et al., 2015a Uehara et al., ,b,c, 2016a . Marmoset P450s have high sequence identities (.85%) to their human P450 counterparts, and most marmoset P450 enzymes generally showed similar substrate specificity to their homologous human P450s, except for P450 2A and 2B enzymes. In this study, we isolated cDNAs of four P450 4F forms from livers. Gene cluster organization, sequence identity, mRNA tissue distribution, and enzymatic characteristics of marmoset P450 4F2, 4F3B, 4F11, and 4F12 were investigated to provide understanding of the metabolism of drugs and fatty acids in marmosets.
Materials and Methods
Chemicals and Enzymes. Ebastine, hydroxyebastine, and carebastine were purchased from Almirall-Prodesfarma (Barcelona, Spain). Leukotriene B 4 and 20-hydroxyleukotriene B 4 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Bufuralol and 19-hydroxybufuralol were purchased from Corning Life Sciences (Woburn, MA) and Toronto Research Chemicals (Toronto, ON, Canada), respectively. Coumarin and midazolam were purchased from Wako Pure Chemicals (Osaka, Japan). Resorufin, 7-ethoxyresorufin, S-warfarin, 7-hydroxywarfarin, and 19-hydroxymidazolam were purchased from Sigma-Aldrich (Tokyo, Japan). Oligonucleotide primers for polymerase chain reaction (PCR) were synthesized by SigmaAldrich. Pooled liver microsomes from marmosets (14 males, sexually mature), cynomolgus monkeys (10 males, aged 2-7 years), and humans (74 males and 76 females, aged 18-82 years) were purchased from Corning Life Sciences. Pooled intestine microsomes from cynomolgus monkeys (3 males, aged 6-7 years) and humans (7 males and 6 females, aged 18-55 years) were purchased from Xenotech (Lenexa, KS). Pooled small intestine microsomes from marmosets were prepared from tissue samples of 20 marmosets (10 males and 10 females, aged .2 years) as described previously (Uehara et al., 2011) . Brains, lungs, livers, kidneys, and small intestines were collected from 20 marmosets at the Central Institution for Experimental Animals (Kawasaki, Japan). Protocols for the animal study were reviewed and approved by the Institutional Animal Care and Use Committee in the Central Institution for Experimental Animals. Anti-human P450 4F antibodies (Hashizume et al., 2001) were donated by Dr. Takanori Hashizume. All other solvents and chemicals used were the highest grade available commercially.
P450 4F cDNA Cloning. Marmoset and human P450 4F cDNAs were cloned from the liver by reverse transcription (RT)-PCR. Total RNAs were extracted from marmoset and human livers using an RNeasy Mini Kit (Qiagen, Valencia, CA). RT reaction was carried out in a mixture containing 1 mg total RNA, oligo (dT) primers, and SuperScript III RT reverse transcriptase (Invitrogen, Carlsbad, CA) at 50°C for 60 minutes according to the manufacturer's instructions. PCR amplification was carried out for 30 cycles; each denaturation at 98°C for 15 seconds, annealing at 60°C for 30 seconds, and extension at 68°C for 3 minutes.
PCR primers used were as follows: cjCYP4F2 (5rt1) 59-CAGCAGAAGAGGAGAG-GAGG-39 and cjCYP4F3B (3rt2) 59-TCAGGGGTCATTTTAGGAAGGG-39 for marmoset P450 4F2, cjCYP4F3B (5rt2) 59-GACCTCACCCTCCATCCTGTA-39 and cjCYP4F3B (3rt2) 59-TCAGGGGTCATTTTAGGAAGGG-39 for marmoset P450 4F3B, cjCYP4F11 (5rt2) 59-GACCTCATCCTCCATCCCATTC-39 and cjCYP4F11 (3rt3) 59-AGGTGGGTGGGTTGATCCGAC-39 for marmoset P450 4F11, cjCYP4F12 (5rt2) 59-GAACAAGCTGCTCCTGACAG-39 and cjCYP4F12 (3rt2) 59-CTATGCA-GAGGTGACAGAAGC-39 for marmoset P450 4F12, hCYP4F2 (5rt1) 59-GAGAG-GAGGTTGTCTGGGAC-39 and hCYP4F2 (3rt1) 59-TTTAGTGGGGTCAGAGTGGG-39 for human P450 4F2, hCYP4F3B (5rt1) 59-GGAGGTTGTGTGGGACAAGG-39 and hCYP4F3B (3rt2) 59-TCTTAGGGTAATTCTAGGCC-39 for human P450 4F3B, hCYP4F11 (5rt2) 59-ATCCTTGCCCCTTTCCACTG-39 and hCYP4F11 (3rt2) 59-CCCACTCACCTCCCTTTCTT-39 for human P450 4F11, and hCYP4F12 (5rt1) 59-GGAGAAGAGGTTGTGTGGGA-39 and hCYP4F12 (3rt1) 59-AAA-CAGGTGGATGGGTCAGA-39 for human P450 4F12. All PCR products were cloned into the pGEM-T easy vector for TA cloning (Promega, Madison, WI), and then the sequence of each insert was confirmed by DNA sequencing. Cynomolgus monkey P450 4F2, 4F3B, 4F11, and 4F12 cDNAs were identified as described previously (Uno et al., 2007) .
Sequence Analyses of P450 4F Forms. The multiple alignment analysis of amino acid sequences was carried out using the Genetyx system (Software Development, Tokyo, Japan). The marmoset genome data were analyzed by BLAT (UCSC Genome Bioinformatics, University of California, Santa Cruz, CA). The amino acid sequence homology with other P450 4F members was analyzed by BLAST (National Center for Biotechnology Information, Bethesda, MD). The phylogenetic tree was constructed by the neighborjoining method using DNASIS Pro (Hitachi Software, Tokyo, Japan). The following amino acid sequences used were from GenBank: human P450 4A11 (NP_000769), 4F2 (NP_001073), 4F3A (NP_000887), 4F3B (NP_001186137), 4F8 (NP_009184), 4F11 (NP_067010), 4F12 (NP_076433), and 4F22 (NP_775754); orangutan P450 4F11 (NP_001127225) and 4F12 (NP_001126132); cynomolgus monkey P450 4F2 (AAZ29444), 4F3B (NP_001270060), 4F11 (AAZ29446), and 4F12 (NP_001270193); rhesus monkey P450 4F8 (NP_001181472), 4F12 (NP_001181489), and 4F22 (NP_001181468); pig P450 4F55 (NP_001231565); rat P450 4F1 (NP_062569), 4F4 (NP_775146), 4F5 (NP_775147), 4F6 (NP_ 695230), 4F17 (NP_001178915), 4F18 (NP_001028858), 4F37 (NP_001258281), and 4F40 (NP_001102830); and mouse P450 4F13 (NP_570952), 4F14 (NP_071879), 4F15 (NP_598888), 4F16 (NP_077762), 4F17 (NP_001094915), 4F18 (NP_077764), 4F37 (NP_001093657), 4F39 (NP_796281), and 4F40 (NP_001095058). For marmoset P450 4F forms, the amino acid sequences deduced from cDNAs isolated in this study were used.
Quantitative RT-PCR. The tissue distribution of P450 4F mRNA expression in marmosets was measured by real-time RT-PCR. Total RNAs were extracted from brains, lungs, livers, kidneys, and small intestines using an RNeasy Mini Kit as described earlier. The first-strand cDNAs were reverse transcribed with random primers (Invitrogen) and SuperScript III RT reverse transcriptase (Invitrogen). Real-time PCR was performed with an ABI PRISM 7300 sequence detection system (Applied Biosystems, Foster City, CA) using Power SYBR Green PCR Master Mix (Applied Biosystems) as described previously (Uehara et al., 2015a (Uehara et al., ,b,c, 2016a . The PCR Fig. 1 . P450 4F cluster in marmosets, macaques, and humans. Marmoset P450 4F genes were located adjacent to PGLYRP2 and RAB8A in the genome region corresponding to human and macaque P450 4F genes. Solid arrows indicate the expressed genes containing a complete open reading frame (ORF). Shaded arrows indicate pseudogenes with a nearly complete ORF. Shorter shaded arrows indicate pseudogenes lacking most part of an ORF. Open arrows indicate the genes that have a complete or nearly complete ORF, but their expression has not been reported. Sizes of the genes and the distance between the genes are not proportionate to the actual measurement. primers used at a final concentration of 400 nM were cjCYP4F2 (5ex2a) 59-ACACATGGGCCTGGTCAAC-39 and cjCYP4F2 (3ex3a) 59-CTTCAG-GAAGCTGTAGAAGAACTTG-39 for marmoset P450 4F2, cjCYP4F3B (5ex2a) 59-GCCCCTTCACCCTCATCATCC-39 and cjCYP4F3B (3ex3a) 59-TCAGGAAGCCATAGAAGACTTCATC-39 for marmoset P450 4F3B, cjCYP4F11 (5ex2a) 59-CATTTTATGCCACCCTGATACCG-39 and cjCYP4F11 (3ex3b) 59-CTTCAGGAAGCCATAGAAAAGCATA-39 for marmoset P450 4F11, and cjCYP4F12 (5ex2a) 59-GCTTGAAGAACTTGACCCAGATATC-39 and dmd.aspetjournals.org cjCYP4F12 (3ex3a) 59-AGGAACCTGATGAAGAGCTCG-39 for marmoset P450 4F12. The PCR conditions were as follows: an initial denaturation for 10 minutes at 95°C, followed by 40 cycles of 95°C for 15 seconds and at 60°C for 1 minute. Individual P450 4F mRNA expression was measured in triplicate for each sample using standard curves created by plotting the threshold cycle versus the log of the amount of PCR amplicon for each P450 4F form. The expression level of each P450 mRNA was normalized to the level of 18S rRNA measured using Eukaryotic 18S rRNA Endogenous Control (Applied Biosystems).
Heterologous Expression of P450 4F Proteins. To prepare the recombinant proteins, expression plasmids of marmoset and human P450 4F forms were constructed using pCW vectors containing a cDNA of human NADPH-P450 reductase as described previously (Uehara et al., 2016c) . The N-terminal modification was performed by PCR using the forward and reverse primers containing the restriction sites of the NdeI and XbaI restriction enzymes (underlined), respectively, including cjCYP4F2 (5exp1bov) 59-CATATGG-CTCTGTTATTAGCAGTTTTTCTGGGCCTCGGGCCG-39 and cjCYP4F2 (3exp2) 59-TCTAGATTAGCTCAGGGGCTCCA-39 for marmoset P450 4F2, cjCYP4F2 (5exp1bov) 59-CATATGGCTCTGTTATTAGCAGTTTTTCTG-GGCCTCGGGCCG-39 and cjCYP4F3B (3exp2) 59-TCTAGATTAGCT-CCGGGGCTCCA-39 for marmoset P450 4F3B, cjCYP4F11 (5exp2bov) 59-CATATGGCTCTGTTATTAGCAGTTTTTCTGGGCCTCGGGCCAGTG-39 and cjCYP4F11 (3exp2) 59-TCTAGATTACTGTGGGTTTGCACCC-39 for marmoset P450 4F11, cjCYP4F12 (5exp1bov) 59-CATATGGCTCTGTTATT-AGCAGTTTTTCTGGGCTTCGGGCCAG-39 and cjCYP4F12 (3exp2) 59-TCTAGATTACTGTGAGCCCGCGT-39 for marmoset P450 4F12, hCYP4F2 (5exp1bov) 59-CATATGGCTCTGTTATTAGCAGTTTTTCTGGGCCTCTG-GCCAGTG-39 and hCYP4F2 (3exp1) 59-TCTAGATTAGCTCAGGGGCTC-CACCCGC-39 for human P450 4F2, hCYP4F3B (5exp1bov) 59-CATA-TGGCTCTGTTATTAGCAGTTTTTCTGGGCCTTTGGCCAATG-39 and hCYP4F2 (3exp1) 59-TCTAGATTAGCTCAGGGGCTCCACCCGC-39 for human P450 4F3B, cjCYP4F11 (5exp2bov) 59-CATATGGCTCTGTTAT-TAGCAGTTTTTCTGGGCCTCGGGCCAGTG-39 and hCYP4F11 (3exp1) 59-TCTAGATTACTGTGAGTTCGCACCCAGG-39 for human P450 4F11, hCYP4F12 (5exp1bov) 59-CATATGGCTCTGTTATTAGCAGTTTTTCT-GGGCCTCAGACCGGTG-39 and hCYP4F12 (3exp1) 59-TCTAGAT-TACTGCAAGCTTACATTCAGG-39 for human P450 4F12, and Human  4F2  93  91  84  81  4F3B  90  93  82  81  4F11  86  86  89  82  4F12  82  82  81  87  Cynomolgus monkey  4F2  91  90  84  82  4F3B  90  91  83  81  4F11  83  85  85  79  4F12  81  81  80  88  Marmoset  4F2  91  84  81  4F3B  83  81  4F11 80 Fig. 3 . A phylogenetic tree of P450 4F amino acid sequences in various species. A phylogenetic tree was created by the neighborjoining method using P450 4F amino acid sequences of the marmoset (cj), human (h), orangutan (ora), cynomolgus monkey (mf), rhesus monkey (mm), pig (pig), rat (r), and mouse (m). Marmoset and human P450 4F forms are shown in boxes. Human P450 4A11 was used as an outgroup. A scale bar indicates an evolutionary distance of 0.1 amino acid substitutions per position.
836 Uehara et al. at ASPET Journals on October 29, 2017 dmd.aspetjournals.org mfCYP4Fs (5exp1bov) 59-GGAATTCCATATGGCTCTGTTATTAG-CAGTTTTTCTGGGCCTCGGGCCGGT-39 and mfCYP4F12 (3exp1) 59-GCTCTAGAGGTGGATGGATCACAGAGTCA-39 for cynomolgus monkey P450 4F12. All PCR products were cloned into pGEM-T easy vectors, and then the inserts were subcloned into pCW vectors using the restriction enzyme sites. Expression plasmids of cynomolgus monkey P450 4F2, 4F3B, and 4F11 were constructed as described previously . Membrane preparation of E. coli DH5a expressing each recombinant P450 4F protein was carried out as described previously (Yamazaki et al., 2002) . The concentration of P450 and NADPH-P450 reductase in each membrane preparation was measured as described previously (Yamazaki et al., 2002) . Measurement of Enzyme Activities. For ebastine hydroxylation, the incubation mixture (0.25 ml) consisted of 40 pmol/ml recombinant protein or 0.5 mg/ml liver or small intestine microsomes, 0.4-500 mM ebastine, an NADPHgenerating system (0.25 mM NADP + , 2.5 mM glucose 6-phosphate, and 0.25 U/ml glucose 6-phosphate dehydrogenase), and 100 mM potassium phosphate buffer (pH 7.4). Reactions initiated by adding the NADPH-generating system proceeded at 37°C for 30 minutes. For the immunoinhibition study, the incubation mixture (0.125 ml) consisted of 12.5 ml anti-human P450 4F antibodies (40 mg/ml) or nonimmune rabbit sera, 40 pmol/ml recombinant protein, or 0.5 mg/ml tissue microsomes from marmosets, cynomolgus monkeys, and humans at room temperature for 30 minutes. The reaction was started by adding 1 mM ebastine (final concentration, 10 mM) and an NADPH-generating system and continued at 37°C for 30 minutes. Reactions were then terminated by the addition of acetonitrile (1.0 ml). The resultant solutions were centrifuged at 10,000g for 5 minutes. The supernatants (1.0 ml) were dried using a rotary evaporator under vacuum and then dissolved in 30% acetonitrile (0.2 ml). Samples (50 ml) were analyzed by reversed-phase high-performance liquid chromatography on a C18 column (5 mm, 250 Â 4.6 mm, Mightysil; Kanto Chemical, Pulau Pinang, Malaysia) at a flow rate of 1.0 ml/min using a mobile phase gradient consisting of 6.3 mM ammonium acetate (pH 4.5) and acetonitrile with monitoring at 256 nm. The gradient elution conditions were 35% acetonitrile (0-3 minutes), 35%-85% acetonitrile (3-25 minutes), 85% acetonitrile (25-30 minutes), and 35% acetonitrile (30-40 minutes). Carebastine, 4-hydroxyebastine, and ebastine were detected with retention times of 12.9, 14.6, and 18.7 minutes, respectively. Leukotriene B 4 20-hydroxylation activity was determined by the method as described (Jin et al., 1998) , with minor modifications. The incubation mixture (0.25 ml) contained 10 pmol recombinant P450 protein, 30 mM leukotriene B 4 , the NADPH-generating system, and 100 mM potassium phosphate buffer (pH 7.4). Reactions were started by adding the NADPH-generating system, incubated at 37°C for 20 minutes, and then terminated by the addition of 4.0 M HCl (25 ml). The resultant solutions were centrifuged at 10,000g for 5 minutes.
Supernatants (50 ml) were analyzed by reversed-phase high-performance liquid chromatography on a C18 column (5 mm, 250 Â 4.6 mm, Mightysil) using isocratic elution by methanol/0.5% phosphoric acid [60:40 (v/v) ] at a flow rate of 1.2 ml/min with monitoring at 270 nm. As a result, 20-hydroxyleukotriene B 4 and leukotriene B 4 were detected with retention times of 8.3 and 20.1 minutes, respectively. 7-Ethoxyresorufin O-deethylation, S-warfarin 7-hydroxylation, bufuralol 19-hydroxylation, and midazolam 19-hydroxylation by recombinant proteins were measured as described previously (Uehara et al., 2015b) . Rates of metabolite formation were determined from standard curves prepared using reference standards. Kinetic parameters for ebastine hydroxylation were estimated from the fitted curves employing MichaelisMenten equations using the KaleidaGraph program (Synergy Software, Reading, PA).
Results
Isolation of Marmoset P450 4F cDNAs. Using the marmoset genome data, the four new marmoset P450 4F genes, namely P450 4F2, 4F3B, 4F11, and 4F12, were found in the P450 4F gene cluster on chromosome 22 (Fig. 1) . To obtain marmoset P450 4F cDNAs, RT-PCR was performed with the gene-specific primers. The four P450 4F cDNAs isolated from livers encoded 520, 520, 524, and 526 amino acids for P450 4F2, 4F3B, 4F11, and 4F12, respectively, which had the characteristic domain of the P450 family including six substrate recognition sites (SRSs) and a heme-binding site, similar to human and cynomolgus monkey P450 4F forms (Fig. 2) . Amino acid sequences of marmoset P450 4F2, 4F3B, 4F11, and 4F12 showed high degrees of identity (85%-93%) to the human and cynomolgus monkey P450 4F counterparts (Table 1) . A phylogenetic tree created using the P450 4F forms of seven species showed that marmoset P450 4F forms clustered closer to the P450 4F forms of primates, including humans, orangutans, rhesus monkeys, and cynomolgus monkeys, than those of dogs, pigs, rats, and mice (Fig. 3) .
Tissue Distribution of Four P450 4F mRNAs in Marmosets. To investigate the expression level of marmoset P450 4F mRNAs in brains, lungs, livers, kidneys, and small intestines, real-time RT-PCR was performed using the gene-specific primers. All four marmoset P450 4F mRNAs were expressed in livers where P450 4F3B mRNA was expressed most abundantly among the P450 4F mRNAs, followed by P450 4F11, 4F2, and 4F12. In addition, P450 4F2 and 4F12 were also abundantly expressed in small intestines (Fig. 4) . These results indicated that marmoset P450 4F forms were expressed in livers and small intestines, the drug-metabolizing organs.
Enzymatic Activities of Marmoset P450 4F Proteins. To assess the catalytic function of marmoset P450 4F enzymes, hydroxylation of leukotriene B 4 and ebastine by recombinant P450 4F proteins and tissue microsomes was analyzed. All marmoset P450 4F enzymes catalyzed leukotriene B 4 20-hydroxylation, a typical human P450 4F probe activity (Table 2 ). In contrast, 7-ethoxyresorufin O-deethylation, S-warfarin 7-hydroxylation, bufuralol 19-hydroxylation, and midazolam 19-hydroxylation activities by recombinant proteins were below the dmd.aspetjournals.org detection limit (,0.002, ,0.0001, ,0.001, and ,0.3 nmol products/ min per nmol P450, respectively). For ebastine hydroxylation, the P450 4F12 enzyme had the highest catalytic activity among the four marmoset P450 enzymes, as it also did in cynomolgus monkeys and humans (Table 3 ). Kinetic analyses indicated that marmoset P450 4F12 effectively catalyzed ebastine hydroxylation (V max /K m , 0.19 ml/min per nmol), similar to those of human and cynomolgus monkey P450 4F forms (V max /K m , 0.41 and 0.56 ml/min per nmol, respectively) ( Fig. 5A ; Table 4 ). In addition, marmoset small intestine microsomes more efficiently catalyzed ebastine hydroxylation (V max /K m , 44 ml/min per mg), compared with cynomolgus monkey and human small intestine microsomes (V max /K m , 23 and 19 ml/min per mg, respectively) ( Fig. 5B ; Table 4 ). These results showed that marmoset P450 4F enzymes were similarly functional to those of humans and cynomolgus monkeys, and P450 4F12 especially effectively catalyzed ebastine hydroxylation. Inhibitory Effects of Anti-P450 4F Antibodies on Ebastine Hydroxylation. To investigate the involvement of P450 4F enzymes for ebastine hydroxylation in liver and small intestine microsomes, inhibitory effects of anti-human P450 4F antibodies were determined. Anti-human P450 4F antibodies (40 mg/ml) substantially inhibited ebastine hydroxylation activities mediated by recombinant marmoset P450 4F12 (Fig. 6A) . Interestingly, ebastine hydroxylation activities by small intestine microsomes from marmosets and cynomolgus monkeys were inhibited (approximately 60% of control activity) under the same conditions, unlike humans. In addition, ebastine hydroxylation activities by small intestine microsomes of marmosets were inhibited by anti-P450 4F antibodies up to 40 mg/ml in a concentration-dependent manner (Fig. 6B) . In contrast, ebastine hydroxylation activities in liver microsomes from marmosets, cynomolgus monkeys, and humans were weakly inhibited (approximately 40% of control activity) (Fig. 6A) . These results indicated that P450 4F enzymes are involved in the metabolism of ebastine in the liver and small intestine in marmosets and cynomolgus monkeys, suggesting an important role of intestinal P450 4F enzymes for ebastine metabolism in marmosets and cynomolgus monkeys.
Discussion
In humans, P450 4F enzymes occupy 15% of total hepatic P450 protein levels, involved in the metabolism of endogenous compounds and xenobiotics (Michaels and Wang, 2014) . In a previous study, de novo gene expression analysis in marmosets indicated expression of the marmoset P450 4F11-like gene in the liver and the 4F12-like gene in the liver, small intestine, and kidney (Shimizu et al., 2014) : however, marmoset P450 4F forms have not been identified and characterized. In this study, we identified four novel P450 4F genes using the marmoset genome data, including P450 4F2, 4F3, 4F11, and 4F12, and the catalytic function of P450 4F proteins heterologously expressed in E. coli was estimated by analyzing leukotriene B 4 20-hydroxylation and ebastine hydroxylation. Amino acid sequences of each marmoset P450 4F form were highly identical (85%-93%) to the human and cynomolgus monkey P450 4F homologs (Table 1 ). Phylogenetic analysis showed that marmoset P450 4F forms were evolutionarily closer to human P450 4F forms than P450 4F forms of other nonprimate experimental animal species, including dogs, pigs, rats, and mice (Fig. 3) .
Among the five tissues analyzed, marmoset P450 4F3B and 4F11 mRNAs were expressed abundantly in the liver, and P450 4F2 and 4F12 mRNAs were expressed abundantly in the liver and small intestine (Fig. 4) . In humans, P450 4F3A and 4F3B mRNAs show a distinct tissue expression pattern owing to tissue-specific alternative splicing; P450 4F3A and 4F3B are predominantly expressed in neutrophils and livers, respectively (Christmas et al., 2001 ). In the marmoset genome, the P450 4F3A-specific exon 3 sequence was found in our preliminary study (data not shown), implying the possibility of P450 4F3 alternative splicing in marmosets, similar to cynomolgus monkeys (Uno et al., 2007) . In addition, human P450 4F2 and 4F12 have been expressed in the liver and small intestine (Bylund et al., 2001; Christmas et al., 2001) , and human P450 4F11 is expressed in the liver (Cui et al., 2000) . Therefore, tissue distribution of P450 4F mRNAs is similar between marmosets and humans. Ebastine hydroxylation rates in the liver and small intestine of marmosets and cynomolgus monkeys were remarkably faster than those of humans (Table 4) . Moreover, ebastine hydroxylation activities by small intestine microsomes from marmosets and cynomolgus monkeys were inhibited by anti-P450 4F antibodies (Fig. 6A) , unlike those of humans, indicating species differences presented in the contribution of P450 4F enzymes for ebastine hydroxylation in small intestines among marmosets/cynomolgus monkeys and humans. Indeed, the major ebastine hydroxylase in intestinal microsomes is P450 2J2 for humans (Hashizume et al., 2002) , but P450 4F12 for cynomolgus monkeys (Hashizume et al., 2001) . Marmoset P450 2J2 was identified recently and was expressed in the liver and small intestine (Uehara et al., 2016b) . Investigation of ebastine metabolism catalyzed by P450 4F and 2J enzymes might help further understand the species differences of ebastine hydroxylation in the small intestine among marmosets, cynomolgus monkeys, and humans.
Besides ebastine, human P450 4F enzymes are involved in the metabolism of other drugs. The human P450 4F12 enzyme metabolizes other antiallergy drugs astemizole and terfenadine, which are human P450 2J2 and 3A4 substrates (Hashizume et al., 2002; Eksterowicz et al., 2014) . Enteric P450 4F2 and/or 4F3B enzymes catalyze O-demethylation of an antiparasitic prodrug, pafuramidine (Wang et al., 2007) . Indeed, O-demethylation of pafuramidine in human intestine microsomes reportedly inhibited 92% of total metabolic activity by anti-P450 4F2 antibodies, whereas the antibodies against P450 3A4/5 and 2J2 showed moderate inhibition (approximately 28%). In addition, P450 4F2 and/or 4F3B enzymes reportedly catalyzed v-hydroxylation of fingolimod, the major elimination pathway (Jin et al., 2011) . v-Hydroxylation of fingolimod in human liver microsomes also inhibited 93% of total metabolic activity by anti-P450 4F2 antibodies, differing from little or no effects by antibodies of P450 2D6, 2E1, and 3A4. P450 4F11 also effectively metabolizes an antibiotic, erythromycin (Kalsotra et al., 2004) . On the basis of high sequence identities of amino acids (.87%), marmoset P450 4F enzymes might also metabolize numerous drugs, similar to those of humans. Further analysis of P450 4F forms for enzymatic characteristics including substrate specificity is needed to understand the P450 4F-dependent metabolism in marmosets.
In humans, P450 4F enzymes are involved in the v-hydroxylation of many eicosanoids such as arachidonic acid, leukotriene B 4 , and prostaglandins (Hsu et al., 2007) and nutrients such as phylloquinone (vitamin K 1 ) (Edson et al., 2013) and tocopherol (vitamin E) (Sontag and Parker, 2002) ; in addition, the substrate selectivity of each P450 4F Fig. 5 . Ebastine hydroxylation activities by recombinant marmoset, cynomolgus monkey, and human P450 4F12 proteins and small intestine microsomes from marmosets, cynomolgus monkeys, and humans. (A and B) Kinetic parameters for ebastine hydroxylation catalyzed by marmoset (circles), cynomolgus monkey (squares), and human (triangles) P450 4F12 proteins heterologously expressed in E. coli (A), and small intestine microsomes (B) from marmosets (circles), cynomolgus monkeys (squares), and humans (triangles).
TABLE 4
Kinetic parameters of ebastine hydroxylation by recombinant P450 4F enzymes and liver microsomes from marmosets, cynomolgus monkeys, and humans Kinetic parameters were determined by nonlinear regression analysis (mean 6 S.E., n = 16 points of substrate concentrations of 0.4-500 mM). Values are based on duplicate determinations. Recombinant P450 protein and intestinal microsomes were incubated with ebastine of optional concentrations for 30 minutes at 37°C in the presence of an NADPH-generating system. (Bylund et al., 2000 (Bylund et al., , 2001 , unlike the other P450 4F enzymes (Jin et al., 1998; Kikuta et al., 1998; Christmas et al., 2001) . A glycine residue (Gly-328) in SRS-4 of P450 4F8 and 4F12 would be likely to contribute to the position specificity for v2-and v3-hydroxylation of arachidonic acid (Stark et al., 2005) . Marmoset and cynomolgus monkey P450 4F12 without any glycine residues in SRS-4 might implicate different position specificity for the hydroxylation of arachidonic acid from human P450 4F12, which may affect processes for activation and deactivation of numerous eicosanoid signaling pathways involving important physiologic functions. Therefore, it is of great interest to investigate the metabolism of various eicosanoids by marmoset P450 4F enzymes in the future. In humans, the P450 4F genes are transcriptionally regulated by nuclear receptors. Indeed, the sequence-specific binding of pregnane X receptor (PXR) in the P450 4F12 gene increased in the presence of rifampicin (Hariparsad et al., 2009 ). In addition, the basal P450 4F12 expression level in human hepatocytes decreased (approximately 80%) by small interfering RNA knockdown of PXR. Therefore, the human P450 4F12 gene is most likely regulated by PXR, indicating the possibility that P450 4F12 induction by PXR ligands leads to drug-drug interactions toward the metabolism of P450 4F12 substrates (e.g., ebastine, astemizole, and terfenadine). In addition, P450 4F11 gene expression is also negatively regulated by nuclear factor kB in the human liver carcinoma cell line (HepG2) (Bell and Strobel, 2012) . These results, together with the similar P450 4F mRNA distribution between marmosets and humans, suggest that marmosets and humans share, at least partly, transcriptional regulation and induction of P450 4F genes. Therefore, marmosets are potentially a suitable model for preclinical safety testing in drug development.
In conclusion, we found four novel marmoset P450 4F genes using the marmoset genome data, and we successfully isolated P450 4F2, 4F3B, 4F11, and 4F12 cDNAs from marmoset livers. Amino acid sequences of the four marmoset P450 4F forms showed high sequence identities (85%-93%) with the homologous P450s of cynomolgus monkeys and humans. In phylogenetic analysis, each P450 4F was more closely related with the human counterpart, compared with other experimental animal species such as mice, rats, and pigs. Four P450 4F mRNAs were abundant in livers and/or small intestines in marmosets, similar to humans. Enzyme assays indicated that all four marmoset P450 4F enzymes were functional, and marmoset P450 4F12 especially effectively catalyzed ebastine hydroxylation. In addition, an inhibition assay using anti-P450 4F antibodies indicated that the P450 4F enzyme might play an important role for ebastine hydroxylation by marmoset small intestine microsomes. These findings indicated that marmoset P450 4F enzymes expressed in livers and/or small intestines were involved in the metabolism of endogenous and exogenous compounds.
